Migden, M. R., Berkin, C., Chang, A. L., & al., E. (2018). Interim Analysis of Phase 2 Results for Cemiplimab, a Human Monoclonal Antibody to Programmed Death-1, in Patients with Locally Advanced Cutaneous Squamous Cell Carcinoma. SKIN The Journal of Cutaneous Medicine, 2, S77. https://doi.org/10.25251/skin.2.supp.77